Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.

Slides:

Advertisements

Similar presentations

Cholestatic liver diseases:

Advertisements

Alcohol Drugs and Hepatitis C, Brewing up a perfect storm COSLA Haymarket, Edinburgh 24 June 2015 Epidemiological overview Professor David Goldberg, Health.

BRÍD MCHUGH C DT204/2 R&D ASSIGNMENT Primary Biliary Cirrhosis.

UK Renal Registry 13th Annual Report

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Haematopoietic stem cell transplantation alongside enzyme replacement therapy in infantile onset lysosomal acid lipase deficiency Ghosh A1, Lum SH2, Jones.

Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry.

Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15

A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease.

Familial Chylomicronemia Syndrome

Updates and Perspectives in Diabetic Dyslipidemia

What is the likely mechanism by which HDL-C reduces coronary heart disease?

A Common Clinical Challenge: Neonatal Jaundice Is it Physiologic or Pathologic?

Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.

Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.

HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.

Chronic Hepatitis C Virus Infection

Starting Strong: Initial Evaluation of the Patient With HCV

An Endocrinology Clinic in Dyslipidemia

Improving the Diagnosis and Treatment of Seizures in Long-term Care

Extrahepatic Manifestations of HCV Infection

Diabetes and Dyslipidemia

More Than Meets the Eye: Identifying Who Is at Risk for NASH

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Updates in Hodgkin Lymphoma

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Glaucoma Progression.

Patient 1: 53-Year-Old Man With CVD Risk Factors

Ask the Onychomycosis Expert, Part 2

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Hunter Syndrome: Why We Need to Diagnose and Treat Early

Select Topics in Cardiovascular Medicine

Managing Complex Hypertension: What Every Physician Should Know

Obesity and Dyslipidemia: How Would You Treat?

Program Goals. Program Goals What is Atopic Dermatitis?

More Than Treatment.

The Mood Disorder Spectrum

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

The Chemical Differences Between EPA and DHA.

Updates in Pyruvate Kinase Deficiency

Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.

Learning Objectives Current Practices in Ruling Out AMI.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Managing Depression is a Team Effort:

Mitral Valve Disease.

Treating to Target in MS

Hyperammonemia: Best Practices for Diagnosis and Treatment

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

5 Things You Need to Know About Hypoparathyroidism

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Hepatitis C: After the Diagnosis

Volume 59, Issue 3, Pages (September 2013)

Managing Age-Related Clinical Issues in Hemophilia

Clinical Issues in AIP:

Program Goals Disclaimers Defining Refractory Seizures.

Volume 58, Issue 6, Pages (June 2013)

LALD Introduction Patient Case Presentation.

UK Renal Registry 16th Annual Report

Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis.

Iron Deficiency in Heart Failure

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Reducing Risk for CV Outcomes

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Lipid Updates From Spring 2019

UK Renal Registry 15th Annual Report

UK Renal Registry 14th Annual Report

Removing Barriers in the HCV Cascade of Care

Evaluating the Totality of Evidence

NAFLD and NASH in Europe and Canada

Presentation transcript:

Lysosomal Acid Lipase Deficiency: Paving the Path for an Early Diagnosis

Program Goals

LAL-D

Prevalence of LAL-D

LAL-D in Adults

Histology

Histology (cont)

Histology: Differential Diagnosis

Confirm the Diagnosis of LAL-D Using an LAL Enzyme Activity Assay

LAL Blood Tests: Dried Blood, Spot Enzyme Assay

Differential Diagnosis

Liver Pathology: Mimics

Making the Final Diagnosis

Hepatic Function Is Progressively Compromised in Patients With LAL-D[a]

LAL-D Is Characterized by Dyslipidemia

LAL-D Is Multisystemic

Wolman Disease

Many Patients Do Not Fit the Classic Lipid Profile

Management and Treatment of LAL-D

ARISE

ARISE: Primary Outcome

ARISE: Secondary Outcomes

LAL-D: Summary

Abbreviations